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Neutralizing antibodies against the neurite growth inhibitory protein
Nogo-A are known to induce regeneration, enhance compensatory
growth, and enhance functional recovery. In intact adult rats and
monkeys or spinal cord injured adult rats, antibodies reached the entire
spinal cord and brain through the CSF circulation from intraventricular
or intrathecal infusion sites. In the tissue, anti-Nogo antibodies were
found inside Nogo-A expressing oligodendrocytes and neurons. Intra-
cellularly, anti-Nogo-A antibodies were colocalized with endogenous
Nogo-A in large organels, some of which containing the lysosomal
marker cathepsin-D. This suggests antibody-induced internalization of
cell surface Nogo-A. Total Nogo-A tissue levels in spinal cord were
decreased in intact adult rats following 7 days of antibody infusion. This
mechanism was confirmed in vitro; cultured oligodendrocytes and
neurons had lower Nogo-A contents in the presence of anti-Nogo-A
antibodies.
These results demonstrate that antibodies against a CNS cell
surface protein reach their antigen through the CSF and can induce its
downregulation.
Introduction
Antibodies are interesting therapeutic agents due to their high
target specificity. CNS targets for therapeutic antibodies in animal
experiments or human trials are currently mainly Alzheimer’s
disease (Gelinas et al., 2004; Hock et al., 2003), neuroinflammatory
diseases (Bieber et al., 2000; Goldman et al., 1997;Warrington et al.,
2000), tumors (Papanastassiou et al., 1995), spinal cord injury
(Schwab, 2004), and stroke (During et al., 2000; Papadopoulos et al.,
2002; Wiessner et al., 2003). Nogo-A is a potent neurite growth
inhibitory protein present in oligodendrocyte and CNS myelin
membranes of the adult CNS and, to a lower degree, on membranes
of subpopulations of neurons (Dodd et al., 2005; Huber et al., 2002;
Hunt et al., 2002; Josephson et al., 2001; Oertle et al., 2003; Wang et
al., 2002a,b). Antibodies against Nogo-A applied to the adult CNS
via the cerebrospinal fluid (CSF) lead to enhanced regrowth of
lesioned axons as well as enhanced compensatory sprouting after
spinal cord injury and stroke in adult rats (Schwab, 2004). An
impressive degree of functional recovery was often seen in these
Nogo antibody-treated animals (Merkler et al., 2001; Papadopoulos
et al., 2002; Schwab, 2004; Wiessner et al., 2003; Liebscher et al.,
2005).
During CNS development, myelin formation and appearance of
Nogo-A in oligodendrocytes parallel the progressive restriction of
axonal growth and plasticity (Kapfhammer and Schwab, 1994;
Keirstead et al., 1992). In the adult CNS, the most plastic regions are
often the lowest in terms of myelin content (Benowitz and Perrone-
Bizzozero, 1991; Kapfhammer and Schwab, 1994). In the postnatal
or adult spinal cord and brainstem, suppression of myelin formation
or the application of a Nogo-A neutralizing antibody restore
plasticity and compensatory sprouting to a level that is normally
seen exclusively within the first few days after birth (Dyer et al.,
1998; Raineteau and Schwab, 2001; Savio and Schwab, 1990;
Schwab, 2004; Thallmair et al., 1998). These results gave rise to
the concept of a stabilizing role of Nogo-A for the adult CNS
(Kapfhammer and Schwab, 1994; Schwab, 2004), probably
assisted by other CNS myelin proteins with neurite growth
inhibitory activities like myelin associated glycoprotein (MAG),
oligodendrocyte myelin glycoprotein (OMgp), Semaphorin 4D and
5A, or certain chondroitin sulfate proteoglycans (Filbin, 2003;
Moreau-Fauvarque et al., 2003; Goldberg et al., 2004; Niedero¨st et
al., 1999). Whereas data on growth-enhancing effects by in vivo
neutralization or gene knockdown are not yet available for MAG or
OMgp, Nogo-A knockout (KO) (Kim et al., 2003; Simonen et al.,
2003) or application of the monoclonal antibody IN-1 neutralizing
Nogo-A led to long-distance regrowth of lesioned adult spinal cord
and brain fibers. Enhancement of regeneration and compensatory
sprouting was obtained with the IgM antibody IN-1 as well as more
recently by new IgG antibodies against Nogo-A (Schnell and
* Corresponding author. Fax: +41 44 635 33 03.
E-mail address: schwab@hifo.unizh.ch (M.E. Schwab).
1
Published in "Molecular and Cellular  Neuroscience 32(1-2): 161-173, 2006"
which should be cited to refer to this work. 
ht
tp
://
do
c.
re
ro
.c
h
Schwab, 1990; Brosamle et al., 2000; Merkler et al., 2001;
Papadopoulos et al., 2002; Wiessner et al., 2003; Liebscher et al.,
2005), by Nogo blocking soluble Nogo receptor fragments (Li and
Strittmatter, 2003) and by blockade of the Nogo receptor subunit
NgR (GrandPre´ et al., 2002). All the antibodies neutralize the in vitro
neurite growth inhibitory effect of recombinant Nogo-A, of Nogo-A
purified from CNS myelin, of crude myelin or brain extracts and of
cultured oligodendrocytes. For the in vivo experiments, they were
applied as hybridoma grafts or as purified antibodies intracerebro-
ventricularly (icv) or intrathecally (it), but their tissue distribution
and fate in the rat CNS have never been studied in detail.
In the present study, we applied different antibodies against
Nogo-A into the lateral ventricles or into the subdural space of the
spinal cord of adult rats and adult Macaque monkeys. We observed
a broad distribution of the antibodies in the brain and spinal cord,
and a good penetration in the adult CNS tissue within 7 days also at
sites far remote from the infusion sites. In contrast to control
antibodies, Nogo-A-specific antibodies were retained in the tissue
and were preferentially localized in the Nogo-A expressing cells
(oligodendrocytes and neurons). Intracellularly, the antibodies were
localized to vacuolar structures which, in part, were labeled with
the lysosomal marker Cathepsin-D. In these structures, Nogo
antibodies were also colocalized with endogenous Nogo-A,
suggesting antibody-mediated internalization and downregulation
of the plasma membrane Nogo-A. Indeed, the overall Nogo-A
level of the tissue was significantly reduced. The antibodies
studied were directed against the Nogo-A-specific region and are
strongly neutralizing and growth-enhancing antibodies in vitro and
in vivo.
Results
Tissue penetration and distribution of CSF transported
anti-Nogo-A antibodies
The highly specific monoclonal antibodies 11C7 and 7B12
directed against the Nogo-A-specific region of rat Nogo-A (Oertle et
al., 2003) have regeneration enhancing effects in vivo: when infused
intrathecally into spinal cord injured rats, they elicited regeneration
of sectioned corticospinal tract fibers and enhanced functional
recovery in a variety of tasks (Liebscher et al., 2005). Increased
functional recovery and enhanced compensatory sprouting were
observed in stroke rats as a consequence of mAB 7B12 infusion
(Wiessner et al., 2003). As shown in Fig. 1, the antibody 11C7 and
mAB hNogo-A against the Nogo-A-specific region of human Nogo
enhanced growth of neurites on monkey brain extract coated culture
dishes in a dose-dependent way.
The antibodies 11C7 and 7B12 were infused into the lateral
ventricle of intact adult rats for 7 days by an osmotic mini pump
implanted under the back skin of the animals. Immunofluorescence
for mouse IgG showed very high signals around the infusion site in
the forebrain cortex (Figs. 2b, c). The contralateral side of the brain,
the thalamus, midbrain, and medulla oblongata were faintly labeled
for the control mouse IgG but showed moderate labeling intensity
for the anti-Nogo antibodies 11C7 and 7B12 (Figs. 2a–c). The
anti-Nogo antibodies but not the control IgGs were also detect-
able on the level of the spinal cord (Figs. 2d–f).
In the spinal cord of lesioned rats with intraventricular infusion
of antibodies for 7 days, anti-Nogo antibodies were highly accu-
Fig. 1. Monoclonal antibodies against rat Nogo-A (mAB 11C7, 7B12, and human Nogo-A (mAB hNogo-A)) improve neurite outgrowth on culture dishes
coated with inhibitory adult monkey brainstem membrane protein extract. P7 rat cerebellar granule cells were grown for 24 h on protein extract coated dishes,
preincubated for 30 min with the respective antibodies at 0.1, 1, or 10 Ag/ml. **P < 0.01. Means T SEM of 3 independent experiments.
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mulated at the lesion site (Fig. 2h). The adjacent spinal cord grey
and white matter regions also contained detectable levels of anti-
Nogo antibodies but not of control antibodies (Figs. 2g, h).
In animals with large unilateral strokes, infusion of antibodies
into the lateral ventricle of the intact side resulted in high anti-
Nogo-A antibody accumulations at the lesion and the infusion
site. Lower but clearly detectable levels of the Nogo-A-specific
antibodies but not the control IgG were detectable in the CNS
tissue remote from the lesion site (data not shown).
Antibodies were also infused intrathecally by a subdural catheter
pushed up from the spinal column level L2 to the midthoracic region
in intact adult rats. Close to the infusion site, all antibodies were
detectable in the tissue, but the anti-Nogo antibody levels were
higher than those of the control IgG (Figs. 3a, d, g, k). In the cervical
spinal cord of these animals, about 2.5 cm rostral to the infusion site,
after 7 days of continuous infusion clear labeling of the spinal cord
grey and white matter was observed in the case of the Nogo-A-
specific antibodies, but not for the control antibody (Figs. 3b, e, h,
l). Spinal cord surface and central canal were more strongly la-
beled. In the forebrain, surface and ventricular labeling as well as
clear labeling of the parenchyma was detected for the anti-Nogo
antibodies in these spinally infused animals (Figs. 3c, f, i, m).
In the two adultMacaquemonkeys infused by a subdural catheter
at cervical level C6 for 8 days with the humanized antibody hNogo-
A, the spinal cord was analyzed at the infusion site and 6 cm caudal
to it. High levels of human antibody were present at the infusion site
(Fig. 4a). Caudally in the thoracic spinal cord, the central canal and
cord surface were strongly labeled, and grey and white matter
showed a homogenous labeling which was specific and clearly over
background (Figs. 4b, e). A similar situation was present in the
forebrain: strong labeling of surface and ventricles and good pene-
tration of the Nogo-A antibody into the parenchyma (Figs. 4c, f).
These experiments show that intraventricular or spinal intrathe-
cal infusion of antibodies against a CNS cell surface antigen lead to
an excellent distribution of the antibody through the CSF circulation
and the brain and spinal cord tissue in adult rats and monkeys.
Whereas the control IgG was washed out rapidly, antibodies against
Nogo-A were retained in the tissue.
CSF anti-Nogo-A antibodies label oligodendrocytes and subtypes
of neurons
Low magnifications of white matter of rats with anti-Nogo-A
antibodies circulating for 7 days in the CSF showed a punctuate
staining which closely resembled the distribution of oligodendro-
cyte cell bodies (Figs. 2e, f, Figs. 5e, f). This staining was observed
in the corpus callosum as well as in the spinal cord after intra-
ventricular infusions and in the spinal cord after spinal intrathecal
Fig. 2. Intact adult rats were infused into the right lateral ventricle with either a control mouse IgG (a, d) or the anti-Nogo-A mAB 11C7 (b, e), or 7B12 (c, f) for 7
days (15 Ag/h). (a–c) Sections close to the infusion sites. High levels of anti-Nogo-A antibodies are retained in the tissue close to the infusion site; levels of the
control mouse IgG are much lower. (d– f) Cervical spinal cord of the same animals showing a similar difference between anti-Nogo-A and control mABs. The
punctuate staining in the anti-Nogo antibody-treated spinal cords corresponds to cell bodies (oligodendrocytes, neurons; see below) labeled by internalized
antibodies. Control antibodies (g) or the anti-Nogo-A antibody 7B12 (h) were infused intraventricularly for 7 days into rats with a partial bilateral dorsal spinal
cord transection. (g) Sagittal sections of the spinal cord showing very low levels of control antibody, including the lesion site (arrowhead). (h) Anti-Nogo
antibodies accumulate in grey and white matter and are enriched at the lesion site. Calibration bar: a–c: 2.1 mm, d– f: 0.6 mm, g, h: 0.8 mm.
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infusions of the anti-Nogo antibodies 11C7 and 7B12. Hybridoma
grafts in the parietal cortex secreting the antibody IN-1 (but not
grafts secreting the control anti-HRP-antibody) also labeled a high
proportion of the cell bodies in white matter (Figs. 6a–c).
To identify the white matter cells labeled by the anti-Nogo-A
antibodies, we performed double immunostainings. In the white
matter, frequent overlap of the infusedNogo antibodies with staining
for endogenous Nogo-A (Figs. 5g– i) or CNPase (not shown), both
markers for oligodendrocytes (Huber et al., 2002; Wang et al.,
2002a,b), was observed. In contrast, GFAP-positive astrocytes were
consistently negative for anti-Nogo antibody staining (Fig. 5k).
In grey matter, in addition to small cell bodies resembling
oligodendrocytes, typical and conspicuous neurons, e.g., pyramidal
cells in the neocortex or motoneurons in the spinal cord, were
labeled by the anti-Nogo-A antibodies (Figs. 5a–f). Often, the
antibody appeared in intracellular granules, suggesting uptake (see
below). Subtypes of neurons, especially large projection neurons,
are known to express Nogo-A and are, therefore, able to bind and
internalize the respective antibodies specifically.
Anti-Nogo antibodies are internalized in vacuoles and lysosomal
structures
High-magnification immunofluorescence and confocal micros-
copy revealed that much of the anti-Nogo antibodies in oligoden-
drocytes and neurons were present in relatively large granular
structures in the cell body, where they accumulated around the
nucleus (Fig. 6). Double immunofluorescence with the lysosomal
marker cathepsin-D revealed that a proportion of these anti-Nogo
antibody containing granules were lysosomes (Figs. 6d, f). As
cathepsin-D is a marker for the more mature lysosomes, some of the
cathepsin-D negative antibody containing structures may be
prelysosomal bodies and early endosomes.
Endogenous Nogo-A colocalizes with internalized anti-Nogo
antibodies in intracellular vacuoles
Endogenous Nogo-Awas labeled by a rabbit antiserum, whereas
the infused mouse anti-Nogo-A antibodies 11C7, 7B12 or IN-1
were visualized with a labeled secondary anti-mouse antibody. In
double immunofluorescence, many of the intracellular granules
which contained internalized anti-Nogo antibodies were also
positive for endogenous Nogo-A (Fig. 7). Oligodendrocyte cell
bodies and neurons showed intracellular Nogo-A staining in the
endoplasmic reticulum as shown earlier (Chen et al., 2000; Huber et
al., 2002). The colocalization of internalized anti-Nogo antibodies
with endogenous Nogo-A in structures resembling lysosomes or
prelysosome organelles suggests that the anti-Nogo antibodies bind
to cell surface Nogo and are internalized subsequently as antibody–
ligand complexes.
Fig. 3. Spinal cords and forebrains of non-lesioned adult rats infused for 7 days at 15 Ag/h intrathecally over the thoracic spinal cord with the anti-Nogo
antibodies 11C7 (a–c) or 7B12 (d– f), or with a control mouse IgG (g– i). Panels (k–m) show animal without infused antibody. Labeling is strongest at the
infusion site (a, d, g, k), where also the control IgG can be seen (g: compare to spinal cord without infused antibodies: k). (b, e, h, l) 2.5 cm rostral to
the infusion site and, somewhat less conspicuously, in the forebrain (c, f, i, m) anti-Nogo antibodies (b, c, e, f) show a clearly visible tissue staining, in
contrast to the faint presence of the control IgG (h, i). The CNS surface is most strongly labeled (arrows). Calibration bar: a–k, b– l: 1 mm, m: 2.2 mm.
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Endogenous Nogo-A levels are reduced in Nogo-antibody infused
spinal cord
Spinal cord cross-sections of intact and spinal cord injured rats
were analyzed by immunohistochemistry andWestern blots for their
endogenous Nogo-A levels, following a 7-day intrathecal infusion
of the anti-Nogo-A antibodies 11C7 or 7B12. In intact rats total
tissue Nogo-A immunoreactivity as seen by immunofluorescence
was reduced to about 70% if compared to the control IgG infused
animals (Figs. 8h, i, l). The effect required a concentration of 3 mg/
ml (15 Ag/h) of infused anti-Nogo antibody 11C7 (Fig. 7l). MAG,
which is partially colocalized with Nogo-A in the innermost myelin
membrane and shares the receptor subunit NgR with Nogo, was not
affected by the Nogo antibodies (Fig. 8l). Results using Western
blots confirmed a corresponding antibody-mediated downregula-
tion of the Nogo-A levels (Figs. 8m, l). In injured spinal cords, a
similar downregulation of endogenous Nogo-A occurred (data not
shown), also in the regions caudal to the lesion where earlier studies
observed axonal regeneration (Brosamle et al., 2000; Liebscher et
al., 2005).
Prolonged exposure of cultured neurons or oligodendrocytes to
anti-Nogo antibodies induces downregulation of Nogo-A
In order to confirm the in vivo observations of endogenous
Nogo-A downregulation in response to Nogo-A neutralization, in
vitro experiments were done on hippocampal neurons and oligo-
dendrocytes. E18 rat hippocampal neurons were grown as
dissociated cultures for 2 weeks in the presence of the anti-Nogo-
A antibody 11C7 or control IgG. Endogenous Nogo-A immunore-
activity at the cell body, quantified through densitometry, dropped
by 30% in presence of 11C7 when compared to the control treatment
(Figs. 8a–e). Optic nerve derived oligodendrocytes, cultured for 4
days in the presence of 11C7 responded similarly, showing a
downregulation of 50% of their Nogo-A level (Fig. 8e).
Discussion
The present results, based on immunohistochemistry combined
with specific cellular markers, show a surprisingly good penetra-
tion of antibodies against Nogo-A into the spinal cord and brain
tissue of adult rats and Macaque monkeys following intraventric-
ular or spinal intrathecal pump infusions. Penetration from the
inner and outer liquor spaces into the tissue resulted in clearly
detectable antibody levels within 7 days. Anti-Nogo-A antibodies
were specifically retained in the tissue and taken up by Nogo-A
expressing cells, i.e., oligodendrocytes and subtypes of neurons.
Intracellularly, colocalization with endogenous Nogo-A suggests
internalization of an antibody–ligand complex. Part of the inter-
nalized antibodies colocalized with lysosomal markers suggesting
subsequent degradation. Indeed, endogenous Nogo-A levels were
significantly decreased in the anti-Nogo antibody infused rat spinal
cord tissue.
Intrathecal drug delivery is a clinical routine method especially
for anti-spastic drugs and treatment of intractable pain (Stempien
Fig. 4. Sections of cervical (a, d) and thoracic (b, e) spinal cord and forebrain (c, f) of adult Macaque monkey infused intrathecally with a humanized anti-
human Nogo-A antibody for 7 days. High levels of the anti-Nogo-A antibody are visible throughout the cervical spinal cord close to the infusion site (a), as
well as in the thoracic spinal cord 6 cm caudal to the infusion site (b). The antibody also reaches and penetrates into the large forebrain of this animal (c).
Central canal and CNS surface are most strongly labeled (arrows). Staining is specific as seen by omitting the secondary antibody on adjacent sections (d– f).
Calibration bars: a, b, d, e: 3 mm; c, f: 5 mm.
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and Tsai, 2000; Turner, 2003). Pumps catheters enter the lumbar
liquor sac from where the drugs flow toward the brain in the
outer, subdural liquor space. Distribution of therapeutic antibodies
following intraventricular or intrathecal injections or infusions has
not been studied so far. Biological effects were seen with
radioimmunoconjugated antibodies against tumours (Papanastas-
Fig. 5. Anti-Nogo-A antibodies are internalized by oligodendrocytes and neurons. (a–c) Cortex of intact rat brain infused intraventricularly with control (a) or
anti-Nogo-A antibodies (b, c). In panel (c), labeling of neuronal cell bodies with shape and position typical for pyramidal cells (insert) can be seen. (d– f) Spinal
cord ventral horn with typical large motoneurons (arrows) and ventral white matter oligodendrocytes (arrowheads). Control IgG infused animals show no
labeling (d). Anti-Nogo-A antibody infused animals (e, f) show large motoneurons containing anti-Nogo antibodies and in white matter many small labeled cell
bodies resembling oligodendrocytes. (g– i) Three cell bodies (arrows) and a large number of cellular processes in spinal cord white matter of a rat infused
intraventricularly for 7 days with the 11C7 anti-Nogo antibody contain the mouse IgG (green, g). All three cell bodies and several of the processes are identified
as oligodendrocytes by their content of endogenous Nogo-A (h). (i) Overlap of panels (g) and (h–k) GFAP-positive astrocyte (green) does not overlap with
anti-Nogo-A antibody containing structures (red) in the spinal cord white matter of an intraventricularly infused rat. Calibration bars: a–c: 1 mm, d–f: 0.1 mm,
g–k: 20 Am.
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siou et al., 1995) and antibodies against bacterial determinants in
meningitis after intraventricular or intracysternal application in
humans (Goldman et al., 1997). In the rat, intraventricular
injections of antibodies against the low affinity NGF receptor
p75 resulted in labeling of p75-positive neurons (Thomas et al.,
1991). In spite of the known rapid turnover of IgGs in the CSF
(Zhang and Pardridge, 2001), the present results show that anti-
Nogo-A IgGs infused into the lateral ventricle or into the spinal
subdural liquor space reach the entire CSF circulation and diffuse
well into grey and white matter of the whole neuroaxis. This is
true in the rat brain as well as following intrathecal infusion in the
much larger Macaque monkey brain and spinal cord. Intrathecal
or intraventricular delivery, therefore, seems an excellent system
for the application of therapeutic antibodies to the CNS. In con-
trast, earlier studies showed that circulating systemic antibodies
against Nogo-A penetrated very poorly into the CNS due to a
rapid resealing of the blood–brain barrier (Merkler et al.,
2003).
Tissue labeling was weak for the control IgG and much higher
for the anti-Nogo-A antibodies. Specific anti-Nogo antibodies are
probably retained in the tissue by binding to Nogo-A on the cell
surface of oligodendrocytes, CNS myelin, and subtypes of neurons
(Dodd et al., 2005; Huber et al., 2002; Oertle et al., 2003; Wang et
al., 2002a,b; Huber et al., 2002). Higher magnification analysis
showed that all the three anti-Nogo-A antibodies used (11C7
directed against aa 623–640; 7B12 directed against aa 760–820
and IN-1 recognizing the Nogo-A-specific region aa173–979)
were internalized in granular structures in the cell bodies of
oligodendrocytes and neurons. Internalization of antibodies bind-
ing to cell surface constituents is a very frequent reaction of cells in
vitro and vivo; typically, the antibodies are internalized as a
complex together with their binding partners (Charles et al., 2000;
Qian et al., 1997; Tolbert and Lameh, 1998; Friedman et al., 2005).
The observed colocalization of the infused anti-Nogo antibodies
with endogenous Nogo-A in the same granular structures suggests
that this mechanism is also operating here. The dimension of these
Fig. 6. Infused anti-Nogo antibodies accumulate in vacuolar organelles containing in part the lysosomal marker cathepsin-D. (a) Section of rat forebrain taken
several mm caudal to a hybridoma graft secreting the antibody IN-1. (b) IN-1 inside a cell in the corpus callosum from the brain shown in panel (a). The anti-
Nogo antibody appears in granular structures. (c) Corpus callosum cell from a rat infused intraventricularly with antibody 7B12 which appears in large granular
structures in the perinuclear area. (d) Large spinal cord motoneurons double labeled for bound/internalized 7B12 antibody (green) and the lysosomal marker
cathepsin-D (red) in an intact rat infused for 7 days with 7B12 intraventricularly. (e, f) Higher magnification of single motoneuron boxed in (d): 7B12 antibody
(e) and overlay with cathepsin-D (f). Calibration bars: a: 2.5 mm, b, c, e, f: 2.5 Am, d: 10 Am.
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granules is that of secondary lysosomes and large endosomes;
indeed, some of these structures were labeled with the late
lysosomal marker cathepsin-D (Delbruck et al., 1994). The binding
of four different antibodies against the Nogo-A-specific region of
Nogo-A in vivo also strongly confirms earlier in vitro data showing
that this region is indeed exposed on the extracellular side of the
membrane (Dodd et al., 2005; Oertle et al., 2003). This feature is
important as one of the most potent active inhibitory sites of Nogo-
A is found in the middle of the Nogo-A-specific region, and
uncertainties existed initially with regard to the topology of the
Nogo-A protein in the membrane due to its lack of a canonical N-
terminal signal sequence (Chen et al., 2000; GrandPre´ et al., 2000;
Oertle et al., 2003).
Antibody-induced internalization and subsequent lysosomal
degradation of Nogo-A could affect the protein levels and its
availability for receptor interactions and neurite growth inhibitory
functions. We found that infusion of anti-Nogo-A antibodies for 7
days induced a dose-dependent downregulation of the overall Nogo-
A immunoreactivity in the intact and in injured rat spinal cord.
Downregulation of cellular Nogo-A could also be observed in vitro:
cultures of optic nerve oligodendrocytes or hippocampal neurons
lost 30–50% of their Nogo-A immunoreactivity by prolonged
exposure to the anti-Nogo-A antibody 11C7. Whether this effect is
entirely due to enhanced, antibody-induced degradation of Nogo-A
leading to lowering of the intracellular stores, or whether the
synthesis of Nogo-A is also affected remains to be studied. The
downregulation was specific for Nogo-A; in the spinal cord, the
myelin protein MAG, which is partially colocalized with Nogo-A in
the ad-axonal inner myelin membrane (Trapp et al., 1984) has
neurite growth inhibitory activity in vitro (McKerracher et al., 1994;
Mukhopadhyay et al., 1994) and shares a receptor subunit (NgR)
with Nogo (Domeniconi et al., 2002; Liu et al., 2002; Wang et al.,
2002a,b) was unaffected. The observed decrease of Nogo-A levels
may be of relevance for the in vivo mechanism of action of
antibodies against Nogo-A in promoting neurite growth following
lesions: in addition to a direct neutralizing effect by binding to and
sterically covering the active sites of Nogo, a fraction of cell surface
Nogo-A is directly removed by antibody-induced internalization and
subsequent degradation. The long distance regeneration of lesioned
spinal axons and the widespread occurrence of compensatory
sprouting following spinal, brainstem or cortical lesions in anti-
Nogo antibody-treated animals (Schnell et al., 1990; Brosamle et al.,
2000; Merkler et al., 2001; Schwab, 2004; Raineteau and Schwab,
2001; Wiessner et al., 2003; Papadopoulos et al., 2002) are in line
with the wide distribution of the CSF anti-Nogo-A antibodies.
In conclusion, the present results show that therapeutic anti-
bodies against a CNS cell surface protein infused into the intact or
lesioned spinal cord or brain CSF compartment are distributed
throughout the CNS, bind to their antigen, and induce internaliza-
tion and degradation of the antibody–antigen complex. In this way,
antibodies against Nogo-A lead to a downregulation of the CNS
Nogo-A levels, a process which may contribute to the regeneration
and plasticity enhancing effects of anti-Nogo-A antibodies in
animals with spinal cord lesions or cortical strokes.
Fig. 7. Neurons in the hippocampus (a–c) and cells in the corpus callosum (d) of rats infused intraventricularly for 7 days with the antibody 7B12 (a–c) or
treated with a IN-1 antibody secreting hybridoma graft (d). Internalized anti-Nogo antibodies (green) colocalize with endogenous Nogo-A (red, b, c, f, g) in the
same intracellular organelles in hippocampal neurons (a–c) and corpus callosum oligodendrocytes (d–g). (e–g) High magnification view of a single cell
boxed in panel (d). Results suggest cointernalization of an antibody– ligand complex. Calibration bars: a–c: 10 Am, d: 18.4 Am, e–g: 3.3 Am.
Fig. 8. Downregulation of endogenous Nogo-A levels by anti-Nogo-A antibodies in vitro (a–e) and in vivo (f–m). (a–e) Cultured rat optic nerve
oligodendrocytes (a, b) and E17 hippocampal neurons (c, d) show decreased endogenous Nogo-A immunoreactivity after exposure to the antibody 11C7 for 4
days (b) or 14 days (d). Single cell densitometry is shown in e (n = 30–40 cells for each experimental condition). (f –k) Spinal cord white matter of
intrathecally infused intact adult rats showed no change in the levels of the astrocyte marker GFAP (f, g), but a conspicuous loss of endogenous Nogo-A
immunoreactivity (h, i, l) by the infusion of anti-Nogo antibodies 11C7 or 7B12 in contrast to the control IgG. Quantification of these results in (l) by
densitometry. Note the unaffected levels of MAG. (k) Downregulation of rat spinal cord Nogo-A after 7 days of mAB 11C7 infusion requires 15 Ag/h (3
mg/ml; 5 Al/h) as an effective minimal antibody dose. (m) Spinal cord Nogo-A protein shown by Western blot after 7 days of 11C7 infusion at 3 mg/ml.
Quantitative data in panels k and l show means T SEM of 3–4 animals per group. *P < 0.05, **P < 0.01 in two-tailed unpaired t test. Calibration bars: a,
f – i: 20 Am.
8
ht
tp
://
do
c.
re
ro
.c
h
9
ht
tp
://
do
c.
re
ro
.c
h
Experimental methods
Antibodies
Three monoclonal antibodies (mABs) against different sites of Nogo-A
were used: mAB 11C7 directed against a 18 amino acid peptide (aa 623–
640) close to the active site of the rat Nogo-A-specific region (Oertle et al.,
2003), the same region against which the neutralizing rabbit antiserum
AS472 was made (Chen et al., 2000). mAB 7B12 has an epitope towards
the C-terminus of the Nogo-A-specific region (in the range of aa 760–820)
and is also a neutralizing antibody (Oertle et al., 2003; Liebscher et al.,
2005). Both mABs bind to the outer surface of living cultured
oligodendrocytes (Oertle et al., 2003). In the monkey experiments, we
used mAB hNogo-A which is a humanized monoclonal antibody raised
against the Nogo-A-specific region of the human Nogo-A sequence. It
recognizes human and primate Nogo-A specifically on Western blots (data
not shown). All antibodies were purified as IgGs and concentrated to 3 mg/
ml in PBS. In some of the experiments, the mAB IN-1 (Caroni and
Schwab, 1988; Chen et al., 2000) was used. It was applied by injection of
hybridoma cells into the parietal cortex as described by Schnell and
Schwab (Schnell et al., 1990).
Control antibodies: mouse serum derived IgG (Chemicon Int.,
Temecula/CA, USA) or a mAB directed against wheat auxin (AMS
Biotechnology, Oxon/UK) was used as control treatments. For hybridoma
AB controls, an anti-HRP antibody was used (Schnell et al., 1990).
Neurite outgrowth assay
Brainstems of adult Cynomolgus monkeys (15 kg body weight) were
rapidly dissected and homogenized with CHAPS; a membrane protein
extract was then prepared as described (Spillmann et al., 1998). The extract
was adsorbed overnight at 1–20 Ag protein per cm2 culture dish on Greiner
4-well dishes (Greiner, Nu¨rtingen, Germany). Dishes were washed three
times with warm Hank’s solution before plating the neurons. The
monoclonal antibodies 11C7, 7B12 (Oertle et al., 2003) or mAB hNogo-
A or a control mouse IgG were preincubated on the dishes at 0.1, 1, or 10
Ag/ml for 30 min and subsequently removed. Postnatal day (P) 6–7 rat
cerebellar granule cells were prepared as described by Niedero¨st et al.
(1999) and plated at 50,000 cells/cm2. Cells were cultured for 24 h in
serum-free medium, fixed, and immunostained for the microtubule
associated protein MAP 1b (Chemicon monoclonal AB, 1:2000) (Gor-
don-Weeks and Fischer, 2000). Four fields at a defined distance to the edge
of the well were quantified for each well using a 40 objective by placing a
horizontal line through the center of the observation field and counting all
intersections of neurites with the line. All cell bodies touching the line were
also counted, and an outgrowth index (neurites per cell body; reflects
neurite length and number) was calculated for each well. All counts were
done blindly on coded experiments.
Neurons and oligodendrocytes grown with anti-Nogo
antibody: cell culture and immunocytochemistry
Primary cultures of embryonic day (E)18 rat hippocampal neurons were
grown at a density of 1.5  104 per 18 mm2 glass coverslip in Neurobasal
medium (Gibco/Invitrogen) supplemented with B27 supplement (Gibco/
Invitrogen), 0.5 mM l-glutamine, and 1.25 mg/ml gentamicin. The
coverslips were placed over a glial feeder cell layer. Hippocampal cultures
were treated with antibody 11C7 or control IgG at 30 Ag/ml immediately
after plating followed by ‘‘booster doses’’ (3 Ag/ml) every fourth day. Cells
were processed for immunocytochemistry for Nogo-A after 14 days in vitro.
Primary cultures of rat oligodendrocytes were prepared from dissected P
6–8 optic nerves. Oligodendrocytes were grown in a high glucose and
sodium pyruvate medium containing several additives including insulin,
triiodothyronine hormone, horse serum, and gentamicin. Oligodendrocyte
cultures were treated with antibodies 11C7 or control IgG (30 Ag/ml) after
36 h in culture. Cells were processed for immunocytochemistry after 5 days
in vitro.
Nogo-A was immunocytochemically detected as described previously
(Dodd et al., 2005). Briefly, cells were fixed using 4% paraformaldehyde and
permeabilized using 0.3% Triton X-100. Upon permeabilization, cells were
incubated with a purified rabbit antiserum against Nogo-A (Oertle et al.,
2003), and the primary antibody was detected using a TRITC-conjugated
secondary antibody. Oligodendrocytes costained for F-actin using phalloidin
showed the typical radial morphology. Densitometry of the immunostained
cells was performed on oligodendrocytes and hippocampal cells using the
ImageJ software. In all densitometric measurements, the cell body was
included as the region of interest.
SDS-gels and Western blotting
Tissues were homogenized and extracted on ice in 20 mM Tris–Cl,
pH 7.4, with 1 mM EDTA, 150 mM NaCl, 1% NP-40 and 0.1% Na-
deoxycholate. Lysates were clarified by centrifugation at 2000 rpm for
15 min, and the detergent-soluble supernatant was saved for further
analysis.
Aliquots (20 Ag of protein) of tissue lysates were separated by SDS-
PAGE under reducing conditions and transferred to Immobilon P-
membranes (PVDF; 0.45 Am; Millipore). Membranes were incubated in
TBST blocking solution (TBS, pH 7.4, 0.1% (vol/vol) Tween-20 and 3%
(wt/vol) TopBlock), followed by incubation overnight in 1.5% blocking
solution with a rabbit antiserum against the Nogo-A/B common N-terminus
(AS Bianca) (Oertle et al., 2003). After washing in TBST, membranes were
incubated with HRP-coupled secondary antibody, washed, incubated in 3%
blocking solution, and incubated overnight with the primary antibody anti-
GAPDH (Abcam; 1:5000). After incubation with the HRP-coupled
secondary antibody, the signals were detected by SuperSignal West Pico
Chemiluminescent Substrate (Pierce). SeeBlue Plus2 Prestained Standard
(Invitrogen) was used to determine the protein size. Autoradiograms were
quantified by Scion Image (Scion Corporation), normalizing the data to
GAPDH expression values.
Animals
Adult 200 g female Lewis rats (n = 18) were used for intrathecal and
intraventricular infusions of antibodies in intact or spinal cord lesioned
animals. Adult male Fisher CDF344 rats (n = 17) were used for the stroke
experiments.
Two male adult Macaque monkeys (Macaca fascicularis) were used in
this study for intrathecal infusion of the humanized antibody hNogo-A
against human Nogo-A. The monkeys, with intact spinal cord, were 7.5 and
8 years old at the time of the experiment and weighed around 15 kg.
All the surgical procedures and animal care were conducted in
accordance with the Guide for the Care and Use of Laboratory Animals
(ISBN 0-309-05377-3; 1996) and approved by the local veterinary
authorities.
Surgical procedures in rats
Pump implantations
Alzet 2ML2 pumps (Alza Corporation, Palo Alto, USA) were used for all
the experiments. Pumps were implanted under the back skin of rats, and
catheters were lead to an Alzet intraventricular infusion cannula cemented on
the skull over the ventricle opposite to the stroke lesion (in case of stroke). For
intrathecal infusions, very fine (32 gauge) catheters (CR3218, ReCathCo,
LLC, 2853-106 Oxford Boulevard, Allison Park, PA 15101) were introduced
into the subdural space over the spinal cord by a L2 laminectomy. Catheters
were pushed up to the midthoracic region. They were secured to the L3 bone
to prevent extrusion. Pumps contained antibodies at a concentration of 3 mg/
ml in PBS. Pumps delivered 5 Al/h.
Spinal cord lesions
Rats were anesthetized with subcutaneous injection of Hypnorm
(Janssen Pharmaceutics, Beerse, Belgium, 120 Al per 200 g body weight)
and Dormicum (Roche Pharmaceuticals, Basle, CH, 0.75 mg in 150 Al per
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200 g body weight). Vitamin A containing eye ointment (Blache, Chauvin
Novopharme AG, Switzerland) was applied to protect the eyes from
dehydration during the relatively long operation procedure.
A bilateral section of the dorsal and dorsolateral funiculus and the
dorsal horn at the spinal level T8 was applied as described earlier (Brosamle
et al., 2000).
Stroke
Rats (male, Fisher CDF344, 250 g) were anesthetized with 2%
isoflurane in a 70/30 (by vol) nitrous oxide/oxygen mixture. The right or
left middle cerebral artery (MCA) and its lenticulostriate branches were
permanently occluded by bipolar electrocoagulation as described previously
(Wiessner et al., 2000). Antibodies were administered 24 h after MCA
occlusion. For icv delivery, a brain infusion cannula (AlzetR brain infusion
kit) was stereotaxically implanted under anesthesia in the intact lateral
ventricle (coordinates: lateral 1.3; anterior–posterior 0.8; dorsoventral
3.8, relative to Bregma) and connected to an Alzet 2ML2 pump.
Surgical procedures in monkeys
Preanesthesia was induced by i.m. injection of ketamine (KetalanR;
Parke-Davis, 5 mg/kg), followed by atropine (0.05 mg/kg, i.m.) to reduce
bronchial secretions. Before surgery, performed under aseptic conditions, the
animal was treated with the analgesic Carprofen (RymadilR, 4 mg/kg, s.c.).
An intravenous catheter was placed in the femoral vein for continuous
perfusion with a mixture of Propofol 1% (FreseniusR) and glucose 4%
solution (1 vol of Propofol and 2 vol of glucose solution), inducing a deep
anesthesia. The animal was then placed in a stereotaxic frame using ear bars.
Heart rate, respiration rate, expired CO2, arterial O2 saturation, and body
temperature were continuously monitored.
The animal was placed in a ventral position, and midline skin incision
was performed from C2 to Th1. A complete C6 laminectomy and an upper
C7 hemi-laminectomy were then performed. The ligamentum flavum was
removed. The dura mater was exposed and incised longitudinally above the
7th and the 8th cervical spinal segments, corresponding to the rostral zone of
the spinal portion covered by the 6th cervical lamina. A polyethylene tube
(10 cm long), connected to an osmotic pump (AlzetR, 2ML1) delivering the
hNogo-A antibody, was inserted below the dura, pushed a few mm rostrally
and attached to the dura with a suture. The osmotic pump was placed and
secured in a cavity made in the mass of back muscles a few centimeters lower
than the laminectomy, on the left side. The tube was secured along its
trajectory with sutures to muscle tissue. The muscles and the skin were
sutured, and the animals recovered from anesthesia 15–30 min after
interruption of the infusion with Profolol. The animals were treated
postoperatively with an antibiotic (Ampiciline 10%, 30 mg/kg, s.c.).
Additional doses of Carprofen were given daily during 1 week (pills of
Rymadil mixed with food).
The monkeys were sacrificed 7 days after implantation of the osmotic
pump. Sedation was first induced with ketamine, as mentioned above,
followed by a deep anesthesia obtained by i.p. injection of a lethal dose of
pentobarbital (90 mg/kg). The animals were perfused transcardially with 0.4
l of 0.9% saline, followed by 4 l of fixative (4% solution of
paraformaldehyde in 0.1 M phosphate buffer, pH 7.6). Perfusion was
continued with 3 solutions of sucrose of increasing concentration (10% in
fixative, 20% and 30% in phosphate buffer).
Histological procedures, immunofluorescence and histochemistry
Rats were fixed under deep Nembutal anesthesia by perfusion through
the heart with 4% buffered paraformaldehyde. Brains and spinal cords of
rats and monkeys were carefully dissected, cryoprotected in 30% sucrose
and sectioned at 40 Am in a cryostat. For all stainings, we used free
floating sections, mostly in a transverse (spinal cord) or coronal (brain)
plane.
Detection of infused mABs: rat-adsorbed anti-mouse antibodies coupled
to biotin were used for mAB 11C7 and 7B12 (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA). An anti-human secondary antibody
was used for the mAB hNogo-A. For double labeling, the following
antibodies were used: the rabbit AS472 (affinity purified) for endogenous
Nogo-A (Chen et al., 2000), rabbit antibodies against GFAP for astrocytes
(Dako, Carpinteria, CA, USA), and a rabbit antibody against cathepsin-D
(Dako) for lysosome localization. All the antisera were visualized by TRITC-
or FITC-coupled corresponding secondary antibodies, or using the ABC-
DAB system (Vector Laboratories, Burlingame, CA, USA).
Sections were analyzed by epifluorescence on a Zeiss Axiophot
Microscope or by confocal microscopy (ZEISS LSM 410). For quantitative
determination of endogenous Nogo-A levels, sections from 10 coded,
randomly mixed rats with different treatments were reacted together
identically for Nogo-A using biotinylated secondary antibodies followed
by the ABC complex, washed and visualized with DAB. Background
corrected optical density of the reaction product was quantified using the NIH
Image program (scion) from digital images of ventral grey and white matter
regions of the spinal cord.
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